1-3 of 3
Andoni Echaniz-Laguna
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments

Clinical Trials & Observations
David Adams, Vincent Algalarrondo, Andoni Echaniz-Laguna
Journal: Blood
Blood (2023) 142 (19): 1600–1612.
https://doi.org/10.1182/blood.2023019884
Published: 2023
Journal Articles

CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies

CME Clinical Trials & Observations
Marie Le Cann, Françoise Bouhour, Karine Viala, Laurence Simon, Céline Tard, Cédric Rossi, Guillaume Morel, Emmeline Lagrange, Laurent Magy, Alain Créange, Maud Michaud, Jérôme Franques, Andoni Echaniz-Laguna, Jean-Christophe Antoine, Marine Baron, Bertrand Arnulf, Angela Puma, Emilien Delmont, Thierry Maisonobe, Véronique Leblond, Damien Roos-Weil
Journal: Blood
Blood (2020) 136 (21): 2428–2436.
https://doi.org/10.1182/blood.2020007092
Published: 2020
Includes: Supplemental data
Journal Articles

Mitochondrial myopathy caused by arsenic trioxide therapy

Brief Report
Andoni Echaniz-Laguna, Aurélien Benoilid, Stéphane Vinzio, Luc-Matthieu Fornecker, Béatrice Lannes, Jean-Pierre Goullé, Frank Broly, Bénédicte Mousson de Camaret
Journal: Blood
Blood (2012) 119 (18): 4272–4274.
https://doi.org/10.1182/blood-2011-10-385138
Published: 2012
Includes: Supplemental data